Literature DB >> 2910478

Correlation between growth inhibition and intranuclear doxorubicin and 4'-deoxy-4'-iododoxorubicin quantitated in living K562 cells by microspectrofluorometry.

M Gigli1, T W Rasoanaivo, J M Millot, P Jeannesson, V Rizzo, J C Jardillier, F Arcamone, M Manfait.   

Abstract

Intranuclear drug concentration in cells treated with doxorubicin (DXR) or with 4'-deoxy-4'-iododoxorubicin (IDX) was measured by means of a quantitative microspectrofluorometric technique recently developed by us. Resolution of free and bound drug contributions in fluorescence emission spectra, as collected from a microvolume of single living cell nuclei, provided concentration data with about 10% indetermination. Uptake of DXR and IDX into the nucleus of K562 cells and DXR-resistant K562/DXR cells could then be studied with a sensitive, nondestructive technique. Growth inhibitory concentrations of K562 and K562/DXR cells, when measured with respect to drug content in the medium, differed by a factor of 25 in the case of DXR and by a factor of three in the case of IDX. By contrast, intranuclear drug concentrations measured at corresponding growth inhibitory concentrations are found to be nearly constant, i.e., independent of cellular-resistant phenotype and of anthracycline structure. This result supports an identical mechanism of action for the two drugs, most probably targeted to the nucleus, and ascribes to intracellular transport the different potency of the two drugs in the two cell lines.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2910478

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  16 in total

1.  Adriamycin binding assay: a valuable chemosensitivity test in human osteosarcoma.

Authors:  N Baldini; K Scotlandi; M Serra; K Kusuzaki; T Shikita; M C Manara; D Maurici; M Campanacci
Journal:  J Cancer Res Clin Oncol       Date:  1992       Impact factor: 4.553

2.  Pharmacokinetics and metabolism of iodo-doxorubicin and doxorubicin in humans.

Authors:  K Mross; U Mayer; K Hamm; K Burk; D K Hossfeld
Journal:  Eur J Clin Pharmacol       Date:  1990       Impact factor: 2.953

3.  The development of new anticancer drugs.

Authors:  F M Arcamone
Journal:  World J Microbiol Biotechnol       Date:  1992-12       Impact factor: 3.312

Review 4.  Mechanisms of amine accumulation in, and egress from, lysosomes.

Authors:  Stephen D B Goldman; Ryan S Funk; Roger A Rajewski; Jeffrey P Krise
Journal:  Bioanalysis       Date:  2009-11       Impact factor: 2.681

5.  Confocal microscopy of idarubicin localisation.

Authors:  M Manfait; J Robert
Journal:  Br J Cancer       Date:  1997       Impact factor: 7.640

6.  Microspectrofluorimetric study of the kinetics of cellular uptake and metabolization of benzo(a)pyrene in human T 47D mammary tumor cells: evidence for cytochrome P1450 induction.

Authors:  F Sureau; L Chinsky; M Duquesne; A Laigle; P Y Turpin; C Amirand; J P Ballini; P Vigny
Journal:  Eur Biophys J       Date:  1990       Impact factor: 1.733

7.  Selective analysis of antitumor drug interaction with living cancer cells as probed by surface-enhanced Raman spectroscopy.

Authors:  I R Nabiev; H Morjani; M Manfait
Journal:  Eur Biophys J       Date:  1991       Impact factor: 1.733

8.  Direct evaluation of intracellular accumulation of free and polymer-bound anthracyclines.

Authors:  T Bogush; G Smirnova; I Shubina; A Syrkin; J Robert
Journal:  Cancer Chemother Pharmacol       Date:  1995       Impact factor: 3.333

9.  Role of the aclacinomycin A--doxorubicin association in reversal of doxorubicin resistance in K562 tumour cells.

Authors:  J M Millot; T D Rasoanaivo; H Morjani; M Manfait
Journal:  Br J Cancer       Date:  1989-11       Impact factor: 7.640

10.  Comparison of conventional chemotherapy, stealth liposomes and temperature-sensitive liposomes in a mathematical model.

Authors:  Astrid Gasselhuber; Matthew R Dreher; Frank Rattay; Bradford J Wood; Dieter Haemmerich
Journal:  PLoS One       Date:  2012-10-17       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.